There is a need to improve the treatment of superficial bladder cancer. One area which holds promise is intravesical gene therapy. Recently, studies undertaken by us have shown that marked tumor regression of bladder cancers occurred after two daily intravesical administrations of an adenovirus encoding human interferon a (Ad-IFNa) using a mouse superficial bladder cancer model in which human bladder tumors are growing. A dose of 1 Â 10 11 particles/ml (P/ml) was used along with 1 mg/ml of Syn3, a gene transfer-enhancing agent. Since clinical studies are being planned using this approach, it became critical to determine if one exposure and lower particle number could be equally effective. We report that indeed a single dose of Ad-IFNa in Syn3 at doses of 1 Â 10 10 -1 Â 10 11 P/ml is highly effective in reducing the size of the tumors, whereas 1 Â 10 9 P/ml was not. Efficacy was also correlated with the level of IFN produced in the urine after treatment. Based on the results of the present studies, a Phase I trial is being planned for superficial bladder cancer, which will involve a single initial treatment with Ad-IFNa/Syn3 and measurement of IFN in the urine over time as an indicator of adequate gene transfer and expression.
Introduction
Current treatment for superficial transitional cell carcinoma of the bladder (TCC) is far from optimal. While most superficial cancers can be managed with periodic transurethral resection (TUR) and surveillance, 60-70% of superficial tumors recur, and worse yet, up to 30% evolve into more aggressive, potentially lethal cancers. The high recurrence rate and the unpredictability of the progression patterns have led to the widespread use of intravesical therapy. Immunotherapy with intravesical BCG very effectively delays progression, but unfortunately this delay does not actually reflect a qualitative change in the underlying biology of the tumor, and patients continue to have substantial risk of eventual progression to invasive, life-threatening cancer. In fact, even with close surveillance and follow-up, more than 50% of patients will eventually recur, and 30% will die of metastatic bladder cancer, despite originally presenting with 'only' carcinoma in situ. 1, 2 Intravesical interferon a2b protein has demonstrated efficacy as a salvage therapy in the scenario of BCG failure, although the durability of the response is limited and most patients relapse within the first year of treatment. Recently, interferon has been combined with BCG in an attempt to enhance the cellular immune response to BCG and improve the response to therapy. 3 This approach has been effective in many cases of BCG refractory TCC, but unfortunately, many of these initial responders relapsed with superficial disease. Radical cystectomy is delayed in the attempt to preserve bladder function with salvage intravesical therapy, with the result that a large number of patients who undergo a delayed cystectomy will eventually die of bladder cancer. These sobering statistics emphasize the double-edged sword of attempted bladder preservation in the face of ineffective intravesical therapy. 1, 2 Intravesical gene therapy is an alternative approach that we are currently evaluating to improve the present status of the treatment for superficial bladder cancer. Our studies have utilized an adenoviral vector encoding the gene for interferon a (Ad-IFNa). We hypothesized that the administration of an adenoviral vector that encodes a secreted gene product, rather than one that encodes a gene for a nuclear or cytoplasmic protein, might provide a superior gene delivery approach to treat superficial bladder cancer because the expression of a secreted gene product could circumvent the requirement that almost every tumor cell need to be transduced, for example, when a tumor suppressor gene delivery approach is utilized. If treatment with Ad-IFNa allows IFNa to be secreted into the bladder tissue/lumen from both transduced normal urothelial and tumor cells, two sources of therapeutic protein could be provided over an extended period. Interferon also can have both a direct antitumor activity and a significant bystander effect, the later including the activation of host effector cells, enhanced apoptosis, and the inhibition of angiogenesis. 4 We have used an excipient, Syn3, to dramatically enhance adenovirus-mediated transduction of the urothelium and superficial bladder tumors because minimal gene transfer occurs without including Syn3 in the formulation. 5, 6 Therefore, Syn3 appears to be an absolute requirement for adenoviral-mediated gene transfer for the treatment of superficial bladder cancer by intravesical administration. To facilitate our efficacy studies, a recently developed superficial bladder tumor model was utilized to monitor the progression of human bladder tumors growing in athymic mice by GFP fluoresence. 7, 8 In our initial study, we found that two daily 1 h intravesical administrations of Ad-IFNa at a concentration of 1 Â 10 11 particles/ml (P/ml), together with Syn3, produced a marked tumor regression in superficial human bladder tumors. 9 All other treatments including Syn3 alone, Ad-bgal/Syn3, Ad-IFN without Syn3, or the IFN protein alone at high concentration showed no effect on tumor growth. 9 In addition, these studies indicated that Ad-IFNa produced a strong bystander effect and surprisingly was effective in bladder cancer cells which were resistant to the IFN protein. 9 The protocol for our initial studies, 9 that is, to instill the Ad-IFN/Syn3 for 1 h on two consecutive days was based on optimization studies using Ad-bgal as a marker. 6 These studies showed that highest gene transfer occurred after 1 h treatment on two consecutive days rather than one treatment or an instillation on day 1 and day 4 as well as indicating that a Syn3 concentration of 1 mg/ml also appeared optimal. 6 Nevertheless, because clinical studies were being planned based primarily on our intial findings, 9 certain practical considerations became important. Since intravesical administration is more complicated than intravenous or subcutaneous therapy as well as the fact that large volumes of the reagent are required (approximately 75 ml/treatment), it became an important practical issue to determine if one exposure of Ad-IFN at 1 Â 10 11 P/ml would be as effective as two treatments using our superficial bladder tumor model.
If one treatment at 1 Â 10 11 P/ml proved effective, the next question to be resolved would be what was the minimal concentration of Ad-IFNa that could produce significant tumor regression. Finally, since measurement of IFN concentration in the urine after treatment will be an important component of the clinical trial, we sought to determine what the concentration of IFNa in the urine was over time at the various doses examined and to analyze if efficacy correlated with the amount of IFNa produced in the urine.
Two Ad-IFNa gene constructs were used in this study: Ad-IFNa2b and Ad-IFNa2 a1. One contained the human IFNa2b gene (Ad-IFNa2b) and the other included a chimeric human 'hybrid' interferon gene consisting of the human a2 N-terminus joined to the human a1 C-terminus (Ad-IFNa2a1). Although IFN activity is generally species restricted, the hybrid interferon (aka 'universal interferon') is active on cells derived from a variety of mammalian species, including mouse and human. 10, 11 Therefore, Ad-IFNa2a1 can be expected to elicit indirect in vivo host effects as well as the direct involvement of Ad-IFNa on the human tumor cells in causing tumor regression and consequently was utilized for all our efficacy studies. We used the other adenoviral viral construct, Ad-IFNa2b, to measure the IFN produced in the urine after Ad-IFN instillation, because an ELISA to accurately quantitate the IFNa2a1 levels in urine was not available, whereas the concentration of IFNa2b protein produced in urine after Ad-IFNa2b/Syn3 administration could be measured using an IFNa2b ELISA kit (PBL).
Materials and methods

Cell lines, vectors, and Syn3
The bladder cancer cell line KU7/GFP clone 6 is stably transfected with the green fluorescent protein and was used for all efficacy studies. 7 Ad-IFNa2a1 12 and AdIFNa2b 13 are both E1-deleted adenoviral constructs with the E1 region replaced with a CMV promoter driving the IFN transgene including the secretory leader sequence. Ad-IFNa2a1 is identical to Ad-IFNa2b except that the Ad-IFNa2a1 transgene is comprised of the cDNA that encodes the N-terminus of the human IFNa2b fused to the C-terminus of the human IFNa1 through a BglII restriction site ((Hu-IFN-aA/D (BglII)), whereas the AdIFNa2b contains the transgene for the human IFNa2b gene. Adenovirus constructs including Ad-bgal as well as Syn3 were obtained from Canji, Inc. (a subsidiary of Schering-Plough).
Superficial tumor formation, treatment, and imaging
Female athymic BALB/c nude mice (age, 6-8 weeks) were obtained from the Experimental Radiation Oncology Department at the MD Anderson Cancer Center (Houston, TX). All studies were approved by the Animal Care and Use Committee at the MD Anderson Cancer Center. The methods for growing superficial KU7/GFP human bladder tumors in athymic mice and their imaging have previously been described. 7, 8 At 2 weeks after the tumor cells were intravesically instilled, the bladders were imaged for the presence of GFP-containing tumors. Anterior, posterior, as well as left lateral and right lateral views were taken as previously described. 8 Mice then received a 100 ml dose of Ad-IFNa2a1/Syn3 intravesically instilled for 1 h. Three concentrations of Ad-IFNa2a1 were used in our experiments: 1 Â 10 11 P/ml, 1 Â 10 10 P/ml, and 1 Â 10 9 P/ml. In one additional group, 1 Â 10 11 P/ml of Ad-IFNa2a1 plus Syn3 was instilled for 1 h on two consecutive days. As controls Syn3 alone or Ad-bgal at 1 Â 10 11 P/ml plus Syn 3 were used. The concentration of Syn3 in all doses was 1 mg/ml in all experiments. In all 11-16 mice were treated per group, except for groups treated with Syn3 alone or Ad-bgal plus Syn3 in which seven and eight mice were treated, respectively. We used fewer mice as controls since we had previously found that two daily treatments had no effect using our model. 9 At 21 days after the IFNa2a1/Syn3 treatment, the bladders were reimaged.
Measurement of IFNa2b urine concentration
Mice were treated with a single intravesical administration as described above at the same three IFNa2b concentrations. Overnight urine collections were obtained from mice using metabolic cages every 3 days (food and water supplied ad libitum). In order to obtain sufficient urine volume for analysis, pooled urine from overnight collections was obtained from cages housing three mice per cage. Urine was collected from three cages (nine mice per dose level) and urine samples from each collection were then assayed for the concentration of human IFNa2b protein using an ELISA kit. As a control, urine was also collected from an untreated group of mice (n ¼ 3).
Statistical analysis
Tumor size was estimated from the pre-and posttreatment bladder area and pre-and post-treatment GFP area measurements using the The Image-Pro Plus version 4.0 for Windows. The percentages of pretreatment GFP area over pretreatment bladder area and posttreatment GFP area over post-treatment bladder area were calculated. The outcome of interest was the change in tumor size from pretreatment to post-treatment. We used a one-sample t-test to determine whether there were statistically significant changes in tumor size within each treatment group. The analysis of variance was used to assess differences in tumor size among treatments. The statistical model included the pretreatment tumor size as well as treatment. We then performed multiple comparisons tests, considering all pair-wise comparisons of the five treatment groups.
Results
Comparison of 1 day treatment with high-dose intravesical Ad-IFNa2a1 to two daily treatments When a single intravesical treatment of 1 Â 10 11 P/ml of Ad-IFNa2a1 was given, we observed a statistically significant tumor regression (Po0.001) (Figure 1a) . Of particular importance, this regression was similar to that found after treatment on two consecutive days (Figure 1b) . All mice treated two times showed marked tumor regression and only one of 11 mice given a single treatment had an increase in tumor size. To better appreciate the tumor regression seen after a single treatment, pre-and post-treatment tumor images for all mice treated once with 1 Â 10 11 P/ml of Ad-IFNa2a1/Syn3 are shown in Figure 2 .
Tumor regression following intravesical Ad-IFNa: effect of dose When the concentration of Ad-IFNa2a was decreased to 1 Â 10 10 P/ml, tumors regressed in eight mice, while three grew over the 21 days following intravesical instillation (Figure 1c) . The change in tumor size from pretreatment to post-treatment at this dose, however, was not statistically significant (P ¼ 0.268), until we excluded one outlier in which the tumor size increased 50%. The results were then statistically significant (P ¼ 0.040). We, therefore, also believe the lower dose of 1 Â 10 10 P/ml Ad-IFNa2a1 had considerable efficacy in causing tumor regression. In contrast, at the concentration of 1 Â 10 9 P/ml of Ad-IFNa2a1, only a minimal effect was observed. The tumor size in 12 of 15 mice was increased with the remaining three mice decreasing in tumor size. The general increase was statistically significant (P ¼ 0.003) (Figure 1d) . The tumors in all mice treated with Syn3 alone (Figure 1e ) or Ad-bgal plus Syn3 (not shown) grew progressively.
Multiple comparisons tests examining all possible pairwise comparisons found that tumor growth in mice treated with Ad-bgal plus Syn3 or Syn3 alone were different from all interferon treatment groups (Po0.001), and that treatment with Ad-IFNa2a1 (1 Â 10 9 P/ml)/Syn3 was different than all other treatments. However, there was no difference in the response to 1 Â 10 10 P/ml compared to 1 Â 10 11 P/ml, whether the 1 Â 10 11 P/ml was administered on a single day (P ¼ 0.158) or on two consecutive days (P ¼ 0.141), nor were two treatments with 1 Â 10 11 P/ml different than one treatment (P ¼ 0.818). The dose-response trend 14 for the change in tumor size yielded a P-value of o0.001 (Figure 1f ).
Dose response of IFNa2b expression in the urine
When we measured IFNa2b levels in the urine of mice receiving intravesical Ad-IFNa2b at the three log-incremental doses in a Syn3 formulation, a dose-dependent expression of IFNa2b was observed over time ( Figure 3) . Peak IFNa2b concentrations in excess of 50 000 pg/ml were detected in mice that had received the highest Ad-IFNa2b dose (1 Â 10 11 P/ml), while a reduction in dose of Ad-IFNa2b by a factor of 10 (1 Â 10 10 P/ml) resulted in a reduction in peak IFNa2b urine concentrations to approximately 10 000 pg/ml.
Mice receiving the lowest dose of Ad-IFNa2b (1 Â 10 9 P/ml) had peak urinary IFNa2b levels of approximately 500 pg/ml. No IFNa2b was detected in the urine from untreated mice (threshold of detection approximately 100 pg/ml). While the urinary IFNa2b levels for mice receiving the lowest Ad-IFNa2b dose had returned to baseline after day 13, urinary IFNa2b levels for the middle-and high-dose groups were similar after day 13 and persisted to, at approximately 1000 pg/ml, day 23.
Discussion
Our initial intravesical studies were undertaken with 1 Â 10 11 P/ml of Ad-IFN and a 1 h exposure on two consecutive days. 9 This schedule was based on what we believed was an optimal strategy from previous studies using b-gal as a marker which indicated that two consecutive intravesical treatments of Ad-b-gal/Syn3 for 1 h gave superior transfection of b-gal to one treatment or an instillation on day 1 and day 4. 6 However, because of the facts that a clinical trial was planned using Ad-IFN/ Syn3, that intravesical therapy is not a trivial procedure, and that 75 ml of reagent will be used for each treatment, it became prudent to determine if one treatment with Ad-IFN/Syn3 also produced significant tumor regression. In the present study, we were pleased to find that this indeed was the case. A significant tumor regression was found 9 P/ml grew progressively, while tumors treated once with Ad-IFNa (1 Â 10 10 P/ml), Ad-IFN (1 Â 10 11 P/ml), or twice with Ad-IFN (1 Â 10 11 P/ml) showed marked tumor regression which was more pronounced with increasing cumulative dose. The Jonckhere-Terpstra 14 trend test yielded a P-value o0.001, confirming the observed relationship between dose and change in tumor size. Each box represents the middle half of the data, while the line across each box represents the median change. The brackets above and below the box denote the range of the data.
Marked tumor regression with Ad-IFN/Syn3
Z Tao et al following exposure to both 1 Â 10 11 and 1 Â 10 10 P/ml. The efficacy of a single treatment was in fact similar to using two treatments on consecutive days at the high dose of 1 Â 10 11 P/ml ( Figure 1 and Benedict et al.
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). However, an Ad-IFNa2a1 concentration of 1 Â 10 9 P/ml was relatively ineffective at inhibiting the growth of the bladder tumors. The results of the present study have, therefore, provided the rationale to use only a single treatment in the initial Phase I trial with Ad-IFN/Syn3 rather than two treatments that was initially envisioned based on our previous results. 9 We also documented that efficacy of Ad-IFNa2a1 was correlated with the concentration of IFN protein in the urine. We had previously shown that a single intravesical treatment with 200 000 IU of IFNa protein in 100 ml (2 MIU/ml) was ineffective in producing tumor regression of bladder tumors and that the levels of IFN protein declined rapidly. 9 In contrast, Ad-IFNa2b in a Syn3 formulation produced high levels of IFNa2b in the urine for a prolonged period. Since the peak concentrations of IFNa in the urine are lower in the Ad-IFN/Syn3-treated mice than the peak concentration that is obtained for a short period when the IFNa protein is intravesically administered and since the efficacy of IFNa protein therapy is low, our results strongly suggest that longer exposures to the IFNa protein will be more efficacious than a single transient bolus of the protein at a high concentration. Analysis of the concentration of IFN in the urine over time as a component of our planned clinical trial should not only provide a comparison between the amount of IFN produced in our mouse model to humans but also will enable the quantization of Ad-IFN gene transfer and expression.
Until recently, obtaining high transduction of adenoviral-mediated genes by intravesical administration has been very limited. However, the addition of Syn3 to adenoviral formulations has changed this situation by dramatically improving the transduction of both normal urothelium and tumor tissue. In addition, the strong bystander effect seen with Ad-IFN as well as its ability to kill tumors that are resistant to the IFN protein itself Female athymic mice received intravesical administration of AdIFNa2b at three doses (1 Â 10 9 P/ml (K), 1 Â 10 10 P/ml ('), 1 Â 10 11 (m) P/ml). Urine was obtained by overnight collections using metabolic cages (three mice/cage; three cages/dose). Urine samples were collected every third day following treatment through day 23 and urine IFN concentrations quantitated using an ELISA (PBL). The urinary IFNa2b concentrations measured over time expressed as pg IFN/ml urine (mean7s.e.m.) are shown.
makes it reasonable to suggest that intravesical Ad-IFN/ Syn3 could be effective in the treatment of recurrent superficial bladder cancer. Planned Phase I/II clinical studies will help to assess the safety, potency, and durability of this approach to determine if Ad-IFNa/ Syn3 is a new paradigm for the treatment of superficial bladder cancer.
